Overview

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Phase:

Phase 3

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Adagrasib
Docetaxel